不同腔内热消融系统治疗大隐静脉反流的前瞻性对比研究
单中心前瞻性对比队列研究纳入153例(160条肢体)大隐静脉反流患者,比较节段性射频消融、1470nm径向光纤激光和1470nm外套管尖端光纤激光的疗效。三组1年闭合率93%-95%,无重大并发症,径向光纤激光组术后早期疼痛和静脉临床严重程度评分改善更优。
要点
- 三种腔内热消融方式治疗大隐静脉反流1年闭合率均达93%-95%,安全性相当。
- 1470nm径向光纤激光组术后1周静脉临床严重程度评分改善优于射频消融和外套管尖端光纤组。
- 术后7天和30天生活质量评分改善径向光纤激光组优于射频消融组,7天优于外套管尖端光纤组。
核心结论
- 三种腔内热消融方式治疗大隐静脉反流有效性和安全性相当。
- 1470nm径向光纤激光在术后早期静脉临床严重程度评分、疼痛和生活质量生理维度评分方面表现更优。
- 术后1年时三种方式的临床和生活质量获益相似。
研究设计与样本
- 单中心前瞻性对比队列研究,纳入连续接受大隐静脉腔内热消融的患者。
- 共153例患者(160条肢体),分为节段性射频消融组(53条肢体)、1470nm径向光纤激光组(55条肢体)和1470nm外套管尖端光纤激光组(52条肢体)。
- 主要结局为临床成功,定义为无大隐静脉反流或再通及无手术相关并发症,于术后7天、30天和1年评估。
主要发现
- 1年大隐静脉闭合率:射频消融组93%,径向光纤激光组93%,外套管尖端光纤激光组95%。
- 术后无重大并发症,三组热诱导血栓发生率分别为4.4%、2.2%和4.4%(P > .5)。
- 术后1周静脉临床严重程度评分径向光纤激光组改善优于射频消融组(P = .05)和外套管尖端光纤组(P = .002)。
- 术后7天生活质量评分变化径向光纤激光组优于射频消融组(-14.3 ± 10.3 vs -7.9 ± 5.9;调整差异6.06;95%CI 1.57-10.55;P = .01)。
- 术后30天生活质量评分变化径向光纤激光组优于射频消融组(-12 ± 8 vs -11.2 ± 7;调整差异5.5;95%CI 1.21-9.81;P = .02)。
临床怎么用
- 三种腔内热消融方式均可用于大隐静脉反流的治疗,可根据设备和操作者偏好选择。
- 若关注术后早期疼痛和生活质量改善,可优先考虑1470nm径向光纤激光。
- 术后需监测热诱导血栓等并发症,尽管本研究中无重大并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of our study was to compare three different endovenous thermal ablation (EVTA) modalities in the treatment of great saphenous vein (GSV) incompetence. METHODS: We performed a single-center, prospective, comparative cohort study that included consecutive patients undergoing EVTA of the GSV. Patients were treated with either segmental radiofrequency ablation (sRFA) or endovenous laser ablation (EVLA) with a 1470-nm dual radial fiber or with a 1470-nm jacket-tip fiber. The clinical classification CEAP (clinical, etiologic, anatomic, pathophysiologic), 10-cm visual analog scale scores for pain, Venous Clinical Severity Scores (VCSSs), and chronic venous insufficiency quality-of-life questionnaire (CIVIQ-20) scores were recorded. The primary outcome was clinical success, which was defined as the absence of reflux or recanalization of the GSV and procedure-related complications, assessed at 7 and 30 days and 1 year postoperatively. The secondary outcomes were the assessment of postoperative pain using the VAS and improvement in the VCSSs and CIVIQ-20 scores. RESULTS: A total of 153 patients (160 limbs) had undergone sRFA (sRFA group; n = 53 limbs), 1470-nm radial fiber EVLA (EVLA-R group; n = 55 limbs), or 1470-nm jacket-tip fiber EVLA (EVLA-J group; n = 52 limbs). The patient demographics, CEAP clinical class, and intraoperative details were comparable among the three groups. The GSV occlusion rate at 1 year was 93% in the sRFA group, 93% in the EVLA-R group, and 95% in the EVLA-J group. No major complications were observed postoperatively. Endothermal heat-induced thrombosis was observed in 2 (4.4%), 1 (2.2%), and 2 (4.4%) patients in the sRFA, EVLA-R, and EVLA-J groups, respectively (P > .5). The VCSS showed greater improvement in the EVLA-R group at 1 week compared with that in the sRFA (P = .05) and EVLA-J (P = .002) groups. Changes in the CIVIQ-20 score were in favor of the EVLA-R group at 7 days (-14.3 ± 10.3 vs -7.9 ± 5.9; adjusted difference, 6.06; 95% confidence interval [CI], 1.57-10.55; P = .01) and 30 days (-12 ± 8 vs -11.2 ± 7; adjusted difference, 5.5; 95% CI, 1.21-9.81; P = .02) postoperatively compared with the sRFA group and at 7 days compared with the EVLA-J group (-14.3 ± 10.3 vs -9.6 ± 7.9; adjusted difference, -4.4; 95% CI, -9.06 to 0.22; P = .05). Analyzing the different components of the CIVIQ-20, pain, and physical scores showed a greater reduction in the EVLA-R group in the early postoperative period compared with that in the sRFA and EVLA-J groups. CONCLUSIONS: All three EVTA modalities showed equal effectiveness and safety for the treatment of GSV reflux. EVLA with the 1470-nm radial fiber showed better outcomes in terms of early postoperative VCSSs and pain and physical CIVIQ scores. The clinical and quality of life benefits were similar for all modalities at 1 year postoperatively.
引用
- Karathanos C, Spanos K, Batzalexis K, et al. Prospective comparative study of different endovenous thermal ablation systems for treatment of great saphenous vein reflux. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 33099037. doi:10.1016/j.jvsv.2020.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。